These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 9189130

  • 1. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 15; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 5. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF.
    J Clin Oncol; 1994 Aug 15; 12(8):1561-71. PubMed ID: 8040668
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Herskovic T, Pereira M, Rubin AD, Goldenberg DM.
    Cancer; 1999 Apr 15; 85(8):1828-42. PubMed ID: 10223579
    [Abstract] [Full Text] [Related]

  • 7. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM.
    Clin Colorectal Cancer; 2002 May 15; 2(1):31-42. PubMed ID: 12453334
    [Abstract] [Full Text] [Related]

  • 8. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.
    Clin Cancer Res; 1997 Sep 15; 3(9):1547-55. PubMed ID: 9815842
    [Abstract] [Full Text] [Related]

  • 9. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 15; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
    Yu B, Carrasquillo J, Milenic D, Chung Y, Perentesis P, Feuerestein I, Eggensperger D, Qi CF, Paik C, Reynolds J, Grem J, Curt G, Siler K, Schlom J, Allegra C.
    J Clin Oncol; 1996 Jun 15; 14(6):1798-809. PubMed ID: 8656248
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 15; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 13. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 15; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
    Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Herskovic T, Markowitz A, Siegel J, Goldenberg DM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [Abstract] [Full Text] [Related]

  • 20. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.